Results 151 to 160 of about 5,123 (202)

Corrigendum: Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: A randomized, open-label, parallel-group, noninferiority phase III trial. [PDF]

Chronic Dis Transl Med
europepmc   +1 more source

Effectiveness of darbepoetin alfa in multiple myeloma patients receiving chemotherapy including novel agents. [PDF]

Blood Res, 2018
Lee SE, Jeon YW, Yoon JH, Cho BS, Eom KS, Kim YJ, Kim HJ, Lee S, Cho SG, Kim DW, Lee JW, Min WS, Min CK.   +12 more
europepmc   +1 more source

Is low hemoglobin at hemodialysis initiation associated with first-year survival among patients treated to target levels soon after dialysis start? [PDF]

, 2018
Inaba, Masaaki, Jacobson, Stefan, Karaboyas, Angelo, Morgenstern, Hal, Pisoni, Ronald, Port, Friedrich, Robinson, Bruce, Sood, Manish, Vanholder, Raymond, Waechter, Sandra   +9 more
core   +1 more source

Correction to: Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial. [PDF]

BMC Nephrol, 2019
Sinha SD, Bandi VK, Bheemareddy BR, Thakur P, Chary S, Mehta K, Pinnamareddy VR, Pandey R, Sreepada S, Durugkar S.   +9 more
europepmc   +1 more source

APPLY: A prospective observational study of clinical practice patterns of darbepoetin alfa use in patients with chemotherapy-induced anemia in Romania. [PDF]

Memo, 2018
Berbec NM, Stanculeanu DL, Badelita NS, Vasilica M, Popovici DI, Colita A, Neacsu C, Iordan A.   +7 more
europepmc   +1 more source

Phase-targeted erythropoietin derivatives for traumatic brain injury: bridging mechanisms to precision therapy. [PDF]

Front Neurol
Sun Y, Song B, Zhang Y, Zhang Y, Zhou L.
europepmc   +1 more source

Efficacy and safety analysis of different treatment schemes of erythropoiesis-stimulating agents for chronic kidney disease with anemia: a meta analysis between 2000-2024. [PDF]

BMC Nephrol
Ou R, Yuan M, Fan W, Li S, Wang X, Guo Z.   +5 more
europepmc   +1 more source

Changes in mean corpuscular volume after erythropoiesis-stimulating agent treatment are associated with renal outcomes in non-dialysis-dependent chronic kidney disease. [PDF]

Clin Exp Nephrol
Son R, Fujimaru T, Kagimura T, Sofue T, Masaki T, Nakayama M, Narita I.   +6 more
europepmc   +1 more source

New Drugs: Darbepoetin alfa

Australian Prescriber, 2002
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Darbepoetin Alfa

Clinical Journal of Oncology Nursing, 2003
Darbepoetin alfa, novel erythropoiesis stimulating protein closely related to human erythropoietin, has been developed for the treatment of chemotherapy-related anaemia in patients with non-myeloid malignancies. In three 12-week, phase II studies in patients with cancer and chemotherapy-related anaemia, subcutaneous darbepoetin alfa, administered in ...
Renita Vance, Kathy Wilkinson
  +8 more sources